|
References Acres B, Apostolopoulos V, Balloul JM, et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother. 2000;48:588-594. Chen Y, Emtage P, Zhu Q, et al. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther. 2001;8:316-323. Disis ML, Gooley TA,
Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein
after active immunization with HER-2/neu peptide-based vaccines. Finn OJ, Jerome KR, Henderson RA, et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev. 1995;145:61-89. Francis RJ, Sharma SK, Springer C, et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer. 2002;87:600-607. Gong J, Chen D, Kashiwaba M, et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci U S A. 1998;95:6279-6283. Goydos JS, Elder E, Whiteside TL, et al. A phase I trial of a synthetic mucin peptide vaccine: induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res. 1996;63:298-304. Ikuta Y, Okugawa T, Furugen R, et al. A HER2/neu-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes. Int J Cancer. 2000;87:553-558. Karanikas V, Thynne
G, Mitchell P, et al. Mannan mucin-1 peptide immunization: influence of
cyclophosphamide and the route of injection. Lees CJ, Apostolopoulos V, Acres B, et al. Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice. Vaccine. 2000;19:158-162. Liau LM, Jensen ER, Kremen TJ, et al. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res. 2002;62:2287-2293. Luhrs P, Schmidt W,
Kutil R, et al. Induction of specific immune responses by polycation-based
vaccines. Machiels JP, van Baren N, Marchand M. Peptide-based cancer vaccines. Semin Oncol. 2002;29:494-502. Morse MA, Clay TM, Colling K, et al. HER2-dendritic cell vaccines. Clin Breast Cancer. In press. Morse MA. Technology evaluation: CEA-TRICOM, Therion Biologics Corp. Curr Opin Mol Ther. 2001;3:407-412. Sheehy ME, McDermott
AB, Furlan SN, et al. A novel technique for the fluorometric assessment of
T lymphocyte antigen specific lysis. Smith M, Burchell JM, Graham R, et al. Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice. Immunology. 1999;97:648-655. |